Braidwell LP Invests $57.49 Million in TransMedics Group, Inc. (NASDAQ:TMDX)

Braidwell LP acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 922,100 shares of the company’s stock, valued at approximately $57,493,000. TransMedics Group accounts for about 1.7% of Braidwell LP’s holdings, making the stock its 23rd largest holding. Braidwell LP owned 2.75% of TransMedics Group as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TMDX. Wilmington Savings Fund Society FSB acquired a new stake in shares of TransMedics Group during the third quarter worth $149,000. Principal Financial Group Inc. lifted its position in TransMedics Group by 260.1% during the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after buying an additional 146,115 shares during the period. APEIRON CAPITAL Ltd acquired a new stake in TransMedics Group in the 4th quarter worth about $468,000. Fiduciary Alliance LLC purchased a new stake in TransMedics Group in the 4th quarter valued at about $247,000. Finally, Talbot Financial LLC acquired a new position in shares of TransMedics Group during the 4th quarter valued at about $300,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on TMDX shares. Piper Sandler reissued an “overweight” rating and issued a $105.00 target price (up from $90.00) on shares of TransMedics Group in a research report on Tuesday, April 29th. Canaccord Genuity Group reissued a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Finally, Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $124.20.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $92.21 on Tuesday. The firm’s fifty day simple moving average is $76.39 and its 200 day simple moving average is $75.75. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37. The firm has a market capitalization of $3.12 billion, a price-to-earnings ratio of 98.10 and a beta of 1.91.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.